During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.
|Number of pages||3|
|Journal||American Journal of Cardiology|
|State||Published - Aug 1 2004|
Bibliographical noteFunding Information:
The Irbesartan Diabetic Nephropathy Trial was sponsored with grant support by Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey, and Sanofi-Synthelabo, Inc., New York, New York.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine